Drugs / Tetrahydrouridine
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01479348 | Nov 2011 → Aug 2017 | breast neoplasm, head and neck neoplasm, lung neoplasm, urinary bladder neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 111 trials | ||||||
| Phase 1 | NCT07006025 | Jun 2025 → Dec 2026 expected | myelodysplastic syndrome | Treebough Therapies | Recruiting | No outcome recorded |
| Phase 1 | NCT06291285 | Feb → Jun 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05816356 | Mar → Jun 2023 | — | EpiDestiny, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04086238 | Oct → Nov 2019 | — | EpiDestiny, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03828084 | Apr → May 2019 | — | EpiDestiny, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02839694 | Jul 2016 → Apr 2017 | germ cell tumor, melanoma, metastatic neoplasm, sarcoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1 | NCT01685515 | Aug 2012 → Jun 2018 | sickle cell disease | Yogen Saunthararajah | Completed | No outcome recorded |
| Phase 1 | NCT01534598 | Mar 2012 → Oct 2019 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00521183 | Jun 2007 → May 2014 | central nervous system neoplasm | Brian Lally | Completed | No outcome recorded |
| Phase 1 | NCT00077051 | Apr 2004 → Jul 2007 | head and neck cancer | University of Miami | Completed | No outcome recorded |
| Phase 1 | NCT00359606 | Apr 1999 → Jun 2012 | neoplasm | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03233724 | Apr 2018 → Oct 2021 | carcinoma of esophagus, malignant pleural mesothelioma, non-small cell lung carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07435636 | Apr 2026 → Apr 2030 expected | clonal hematopoiesis, myeloid hemopathy | Clinical Hub for Interventional Research (CHOIR) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05405114 | Jul 2022 → Jul 2025 | sickle cell disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT02664181 | Jun 2017 → Jul 2019 | non-small cell lung carcinoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00978250 | Aug 2009 → Apr 2019 | breast neoplasm, head and neck neoplasm, lung neoplasm, urinary bladder neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT02846935 Background | Apr 2017 → Jan 2018 | T-cell non-Hodgkin lymphoma, aggressive B-cell non-Hodgkin lymphoma, indolent B-cell non-Hodgkin lymphoma | Yogen Saunthararajah | Completed | No outcome recorded |
| Phase 0 | NCT02847000 Background | Dec 2016 → Oct 2017 | pancreatic adenocarcinoma | Yogen Saunthararajah | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01041443 Background | Dec 2009 → Oct 2013 | acute myeloid leukemia, myelodysplastic syndrome | City of Hope Medical Center | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tetrahydrouridine | “A Study to Investigate the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Decitabine and Tetrahydrouridine (NDec) When Administered Either as a Modified Release...” NCT06291285 ↗20“The goal of this clinical trial is to learn about the safety and effectiveness of the combination drug Tetrahydrouridine (THU) and decitabine (DEC) to treat patients with...” NCT07006025 ↗ “FdCyd (also called 5-fluoro-2'-deoxycytidine) and THU (also called tetrahydrouridine) are experimental cancer treatment drugs.” NCT01534598 ↗ “Decitabine/Tetrahydrouridine (THU) Combination Modified Release Capsules (5 mg/250 mg)” NCT03828084 ↗ “Tetrahydrouridine” NCT00359606 ↗ “Tetrahydrouridine” NCT04086238 ↗ |
| Known as | NSC-112907-D | ChEMBL registry synonym — accepted as the source's own label CHEMBL2311128 ↗ |
| Known as | NSC112907 | “the CD inhibitor tetrahydrouridine (THU; NSC112907)” PMID 26321472 ↗ Sep 2015 |
| Known as | THU | “The goal of this clinical trial is to learn about the safety and effectiveness of the combination drug Tetrahydrouridine (THU) and decitabine (DEC) to treat patients with...” NCT07006025 ↗8“Decitabine/Tetrahydrouridine (THU) Combination Modified Release Capsules (5 mg/250 mg)” NCT03828084 ↗ “decitabine (Dec) (2.5 mg) and tetrahydrouridine (THU) (125 mg) minitablets” NCT07435636 ↗ “Tetrahydrouridine (THU) is supplied as 250 mg/capsule” NCT02847000 ↗ “Co-administered tetrahydrouridine (THU) inhibits CDA” PMID 41161613 ↗ Oct 2025 “Tetrahydrouridine (THU) makes DAC last longer.” NCT02839694 ↗ “Tetrahydrouridine (THU)” NCT03233724 ↗ “THU” NCT00359606 ↗ |
| Known as | U-23284 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2311128 ↗ |
| Action | Inhibit | “the CD inhibitor tetrahydrouridine (THU; NSC112907)” PMID 26321472 ↗ Sep 2015 |
| Modality | Small molecule | “combined 2 small molecules-decitabine to deplete DNMT1 and tetrahydrouridine (THU)” PMID 28880867 ↗ Sep 2017 |
| Route | Intravenous | “Patients receive tetrahydrouridine IV over 5 minutes followed by cytochlor IV for 3 days on week 1 and 5 days a week on weeks 2-4” NCT00077051 ↗ |
| Target | CDA | “inhibit cytidine deaminase (CDA)” PMID 28880867 ↗ Sep 2017 |